Awards as PI
| Program Type | Institution | Grant Title | Award Value |
|---|---|---|---|
| Clinical Trial Stage Projects | Immusoft Corporation | A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1 | $8,000,000 |
| Therapeutic Translational Research Projects | Immusoft Corporation | MPS II: Plasma cell delivery of iduronate sulfatase | $3,994,676 |
Total: $11,994,676.00 |